c-KIT Mutation Analysis, Blood, Bone Marrow
c-KIT is a proto-oncogene that encodes a Type-III transmembrane tyrosine kinase receptor. c-KIT and its ligand stem cell factor play a key role in survival, proliferation, differentiation, and functional activation of hematopoietic progenitor cells. c-Kit is expressed at high levels in hematopoietic stem cells, mast cells, melanocytic cells, germ cells, and the interstitial cells of Cajal. c-KIT mutations are reported in nearly all systemic mastocytosis cases with the most common being Asp816Val c-KIT mutation, 20% – 40% of core-binding factor (CBF) acute myeloid leukemia (AML) cases (those with t(8;21)(q22;q22) and inv(16)(p13q22) genomic rearrangements), and approximately 20% of assayed high-grade myelodysplastic syndrome (MDS) and MDS-derived AML patients.
A c-KIT mutation in AML confers increased risk of relapse and decreased overall survival. c-KIT mutation is also seen in 80 - 85% of gastrointestinal stromal tumors (GIST, GI Stromal Tumor). c-Kit (CD117) antigen is usually detected by IHC (immunohistochemistry). Identification of this mutation can lead to improved patient care. For example, a tyrosine kinase inhibitor, such as imatinib, has been evaluated to treat GI stromal tumors, systemic mastocytosis and c-KIT-positive AML and MDS. The Asp816Val mutation in systemic mastocytosis is relevant to patient therapy because it confers resistance to the drug imatinib. The treatment was found effective as a single reagent or combination therapy in those without this mutation.
- As an aid in diagnosis of mastocytosis
- As an aid in evaluation of acute myeloid leukemia
- As an aid in evaluation of myelodysplastic syndrome
- As an aid in diagnosis of gastrointestinal stromal tumors (GIST)
- As an aid in diagnosis of melanoma
- Disease management and therapy monitoring
Increased in (positive for mutation):
- Systemic mastocytosis
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Myelodysplastic syndrome derived AML
- Gastrointestinal stromal tumors
- Myeloproliferative disorders
- Melanoma
- Lymphoma
- Seminoma
Negative (Mutation not detected)
- Polymerase Chain Reaction (PCR) and ASPE
- High Performance Liquid Chromatography (HPLC)
- DNA Sequence Analysis
Whole blood, bone marrow.
- J Leukoc Biol. 2000 Feb;67(2):135-48. [PMID: 10670573]
- Hematol Oncol Clin North Am. 2000; Jun;14(3):517-35. [PMID: 10909038]
- Br J Haematol. 2003; 121(5):775-7.PMID: 12780793
- Blood. 2005; 106(8):2865-70.PMID: 15972446
- Leuk Res. 2006; 30(10):1235-9.PMID: 16533529
- J Clin Oncology. 2006; 24(24):3904-11.P [PMID:16921041]